Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol.
| Autor: | Kuba VM; Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione - IEDE, Rio de Janeiro, Brazil., Teixeira MA, Meirelles RM, Assumpção CR, Costa OS |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Climacteric : the journal of the International Menopause Society [Climacteric] 2013 Feb; Vol. 16 (1), pp. 54-61. Date of Electronic Publication: 2012 May 28. |
| DOI: | 10.3109/13697137.2012.672843 |
| Abstrakt: | Objective: To evaluate the influence of dydrogesterone on estimated cardiovascular risk of users of hormone replacement therapy (HRT) (with percutaneous 17β-estradiol in monotherapy and in combination with dydrogesterone) and HRT non-users through the Framingham score tool for a period of 2 years. Methods: Framingham scores were calculated from the medical records of patients treated for at least 2 years with 17β-estradiol alone or in combination with dydrogesterone, along with HRT non-users, through the analysis of patient medical records, followed for at least 2 years at Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione. Results: Improvements in lipid profile, glucose and blood pressure levels, which reduced the estimated cardiovascular risk, were observed in the 17β-estradiol group. Similar changes were observed in the users of 17β-estradiol + dydrogesterone, suggesting that this progestogen does not attenuate the effects caused by 17β-estradiol. Conclusions: Both HRT groups showed a reduction in their Framingham score. In contrast to data from other HRT investigations on cardiovascular risk, these formulations proved to be safe, even in the first year of use. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|